Skip to main content

Table 2 Event rates of hospitalisation for HF, MACE and all-cause mortality according to second-line therapy

From: Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study

  Heart failure hospitalisation MACE All-cause mortality
No events Rate per 1000 py No events Rate per 1000 py No events Rate per 1000 py
DPP-4 inhibitors 203 6.9 (6.0–7.9) 398 13.5 (12.2–15.0) 542 18.3 (16.8–19.9)
GLP-1 receptor agonists 151 5.9 (5.0–6.9) 261 10.1 (8.9–11.4) 285 11.0 (9.7–12.3)
SGLT-2 inhibitors 19 4.9 (3.0–7.7) 36 9.3 (6.5–12.9) 45 11.6 (8.5–15.5)
Sulfonylurea 94 5.5 (4.4–6.7) 236 13.8 (12.1–15.7) 330 19.2 (17.2–21.4)
Insulin 156 11.7 (9.9–13.7) 265 19.9 (17.5–22.3) 663 49.3 (45.6–53.2)